MeCo Diagnostics has developed the first and only clinically validated predictive biomarker test to unlock antifibrotic therapy for breast cancer, harnessing a high-efficacy, low-toxicity, generic-emergent, FDA-approved drug to prevent recurrence. Our Phase 2 trial showed an unprecedented improvement in survival rate for High MeCo Score patients. We have 100+ years of diagnostics experience, prestigious partnerships, and high-impact publications.